Recognition of Zinc Transporter 8 and MAP3865c Homologous Epitopes by Hashimoto’s Thyroiditis Subjects from Sardinia: A Common Target with Type 1 Diabetes?

Speranza Masala¹, Davide Cossu¹, Mario Palermo², Leonardo Antonio Sechi¹*

¹ Università degli Studi di Sassari, Dipartimento di Scienze Biomediche, Sezione di Microbiologia e Virologia, Sassari, Italy, ² Department of Endocrinology, Azienda Sanitaria Locale (ASL) 1, Sassari, Italy

Abstract

*Mycobacterium avium* subspecies *paratuberculosis* (MAP) asymptomatic infection has been previously linked to Type 1 diabetes (T1D) and Multiple Sclerosis. An association between MAP infection and Hashimoto’s thyroiditis (HT) was also proposed only in a case report. This study aimed to investigate the robustness of the latter association, testing a large cohort of HT and healthy control (HCs) subjects, all from Sardinia. Prevalence of anti-MAP3865c Abs was assessed by indirect enzyme-linked immunosorbent assay (ELISA). Moreover, given that human ZnT8 is specifically expressed in the pancreatic β-cells, in the follicle epithelial cells and in the parafollicular cells of the thyroid gland, we also tested ZnT8 epitopes homologues to the MAP3865c immunodominant peptides previously identified. Indeed, Abs targeting MAP3865c and ZnT8 homologous regions display similar frequencies in patients and controls, thus suggesting that Abs recognizing these epitopes could be cross-reactive. A statistically significant difference was found between HT patients and HCs when analyzing the humoral response mounted against MAP3865c/ZnT8 homologues epitopes. To our knowledge, this is the first report, which provides statistically significant evidence sustaining the existence of an association between MAP seroreactivity and HT. Further studies are required to investigate the relevance of MAP to HT, aimed at deciphering if this pathogen can be at play in triggering this autoimmune disease. Likewise, genetic polymorphism of the host, and other environmental factors need to be investigated.

Citation: Masala S, Cossu D, Palermo M, Sechi LA (2014) Recognition of Zinc Transporter 8 and MAP3865c Homologous Epitopes by Hashimoto’s Thyroiditis Subjects from Sardinia: A Common Target with Type 1 Diabetes? PLoS ONE 9(5): e97621. doi:10.1371/journal.pone.0097621

Editor: Francesco Dotta, University of Siena, Italy

Received December 16, 2013; Accepted April 22, 2014; Published May 15, 2014

Copyright: © 2014 Masala et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the Sardinian Region L.R.7 2009 and 2010 Progetti di ricerca di base-, PRIN MIUR Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale <Bando PRIN 2009>: Protocollo: 20092YECDZ and Italian Ministry of Health, “Finalized Research” Protocollo: RF-2009-1545765, to LAS. The present publication was produced as part of the RAS research project selection code 06/A3-10, developed at Sassari University by Speranza Masala and supported by P.O.R. Sardinia F.S.E. 2007–2013, Axis IV human capitals, Line of Business I.3.1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: sechilla@uniss.it

Introduction

Hashimoto’s thyroiditis (HT) is a chronic inflammatory condition affecting the thyroid gland. The hallmark of this disease is the abundant lymphocyte B and T infiltrate, resulting in thyroid destruction. It involves both humoral and cellular responses against two thyroid autoantigens: thyroid peroxidase (TPO) and thyroglobulin (TG) [1]. HT is a multifactorial disease stemming from an interaction between genetic and environmental risk factors [2,3]. It has been proposed that *Mycobacterium avium* subspecies *paratuberculosis* (MAP) may be one of the environmental factor at play in triggering HT disease [4,5], but the assumption made was not supported by statistically significant data.

MAP specifically colonizes the mucosa-associated lymphoid tissue (MALT) of the small intestine, where it resides inside the intraepithelial macrophages [6] causing Johne’s disease (JD) in ruminants [7] and it is associated with Crohn’s disease (CD) in humans [8]; moreover, it has been linked to some extradigestive diseases such as type 1 diabetes (T1D) [9–11] and multiple sclerosis (MS) [6,12]. Indeed, an increased serological prevalence of anti-MAP antibodies (Abs) have been reported in T1D patients from Sardinia [9–11], from continental Italy [12], elsewhere [13], and in MS Sardinian subjects [14].

Sera from all the participants included in this case-control study (107 HT patients and 100 HCs) were tested by indirect enzyme-linked immunosorbent assay (ELISA) in order to investigate the prevalence of anti-MAP3865c and anti-ZnT8 antibodies in Sardinia. Abs produced in reaction to MAP3865c peptides are capable of cross-reacting with the homologue ZnT8 peptides of the human body, including the ones located in the thyroid tissue. Indeed, ZnT8 is primarily expressed in the pancreatic β-cell, but it is also specifically expressed in the follicle epithelial cells and parafollicular cells of the thyroid gland [15]. In view of the evidence accounting for a cross-recognition of MAP3865c/ZnT8 homologues sequences in T1D subject [9,10,12] and due to the recently proposed theory which pictures MAP as one of the HT environmental trigger, acting trough a molecular mimicry...
**Table 1.** Hashimoto’s Thyroiditis patients.

| Identity | Gender | Age at incl. | ‡Anti TG | †Anti TPO | MAP3865c125–133 | Znt8178−186 | MAP3865c133–141 | Znt8186−194 | MAP3865c262–275 |
|----------|--------|--------------|----------|----------|-----------------|------------|-----------------|------------|-----------------|
| HT.1     | F      | 56           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.2     | F      | 63           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.3     | F      | 73           | +        | +        | −               | −          | −               | −          | −               |
| HT.4     | F      | NA           | +        | −        | −               | −          | −               | −          | −               |
| HT.5     | F      | 52           | −        | NA       | +               | +          | +               | +          | +               |
| HT.6     | F      | 31           | NA       | NA       | −               | +          | +               | +          | +               |
| HT.7     | F      | 43           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.8     | F      | 53           | +        | +        | +               | +          | +               | −          | −               |
| HT.9     | F      | 51           | +        | −        | −               | −          | −               | −          | −               |
| HT.10    | F      | 62           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.11    | F      | 20           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.12    | F      | 63           | +        | −        | −               | −          | −               | +          | +               |
| HT.13    | F      | 36           | −        | +        | −               | −          | −               | −          | −               |
| HT.14    | F      | 34           | +        | +        | +               | +          | +               | +          | +               |
| HT.15    | F      | 36           | −        | +        | −               | −          | −               | +          | +               |
| HT.16    | F      | 55           | −        | +        | −               | −          | −               | −          | −               |
| HT.17    | F      | 66           | NA       | NA       | +               | +          | +               | +          | +               |
| HT.18    | M      | 45           | −        | NA       | +               | +          | −               | +          | +               |
| HT.19    | F      | 63           | −        | −        | −               | −          | −               | −          | −               |
| HT.20    | F      | 33           | +        | −        | +               | −          | −               | −          | −               |
| HT.21    | M      | 60           | NA       | NA       | +               | −          | −               | −          | −               |
| HT.22    | F      | 32           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.23    | F      | 18           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.24    | M      | 57           | −        | +        | −               | −          | −               | −          | −               |
| HT.25    | F      | 22           | NA       | NA       | −               | −          | −               | +          | −               |
| HT.26    | F      | 52           | +        | +        | +               | +          | +               | +          | +               |
| HT.27    | F      | 56           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.28    | F      | 40           | NA       | NA       | −               | −          | −               | −          | −               |
| HT.29    | F      | 59           | −        | −        | −               | −          | −               | −          | −               |
| HT.30    | F      | 53           | −        | +        | −               | −          | −               | −          | −               |
| HT.31    | F      | 26           | +        | −        | −               | −          | −               | −          | −               |
| HT.32    | F      | 65           | −        | −        | +               | +          | +               | −          | −               |
| HT.33    | F      | 48           | +        | +        | −               | −          | −               | −          | −               |
| HT.34    | F      | 66           | +        | +        | −               | −          | −               | −          | −               |
| HT.35    | F      | 58           | NA       | NA       | −               | −          | −               | −          | −               |
| Identity | Gender | Age at incl. | ‡Anti TG | †Anti TPO | MAP3865c123–133 | ZnT8178–186 | MAP3865c133–141 | ZnT8186–194 | MAP3865c262–275 |
|----------|--------|-------------|----------|-----------|-----------------|-------------|-----------------|-------------|-----------------|
| HT.36    | M      | 44          | –        | –         | –               | –           | –               | –           | –               |
| HT.37    | F      | 59          | +        | +         | –               | –           | –               | –           | –               |
| HT.38    | F      | 40          | ++       | +         | +               | +           | +               | –           | –               |
| HT.39    | F      | 35          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.40    | F      | 44          | –        | –         | –               | –           | –               | –           | –               |
| HT.41    | M      | 14          | NA       | NA        | +               | –           | –               | –           | –               |
| HT.42    | M      | 73          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.43    | F      | 43          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.44    | F      | 62          | –        | –         | –               | –           | –               | –           | –               |
| HT.45    | M      | 46          | +        | +         | +               | –           | –               | –           | +               |
| HT.46    | F      | 49          | +        | NA        | –               | –           | –               | –           | –               |
| HT.47    | F      | 61          | +        | +         | –               | –           | –               | –           | –               |
| HT.48    | F      | 51          | –        | +         | +               | –           | –               | +           | –               |
| HT.49    | F      | 62          | –        | –         | +               | +           | +               | +           | –               |
| HT.50    | F      | 42          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.51    | F      | 54          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.52    | F      | 53          | –        | +         | –               | –           | –               | –           | –               |
| HT.53    | F      | 15          | +        | +         | –               | –           | –               | –           | –               |
| HT.54    | F      | 46          | NA       | NA        | –               | –           | +               | +           | –               |
| HT.55    | F      | 45          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.56    | F      | 51          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.57    | F      | 54          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.58    | F      | 17          | NA       | NA        | +               | +           | +               | +           | –               |
| HT.59    | M      | 48          | +        | +         | –               | –           | –               | –           | –               |
| HT.60    | F      | 28          | +        | +         | –               | –           | –               | –           | –               |
| HT.61    | F      | 37          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.62    | F      | 35          | +        | +         | –               | –           | –               | –           | –               |
| HT.63    | F      | 36          | –        | –         | +               | +           | +               | +           | +               |
| HT.64    | F      | 14          | +        | +         | –               | –           | –               | –           | –               |
| HT.65    | F      | 54          | NA       | NA        | –               | –           | –               | –           | –               |
| HT.66    | F      | 44          | +        | +         | –               | –           | –               | –           | –               |
| HT.67    | F      | 45          | –        | –         | –               | –           | –               | –           | –               |
| HT.68    | F      | 28          | NA       | NA        | +               | +           | +               | –           | +               |
| HT.69    | F      | 62          | +        | +         | –               | –           | –               | –           | –               |
| HT.70    | F      | 45          | –        | NA        | –               | –           | –               | –           | –               |
**Table 1.** Cont.

| Identity | Gender | Age at incl. | ‡Anti TG | †Anti TPO | MAP3865c<sub>125–133</sub> | Znt8<sub>178–186</sub> | MAP3865c<sub>133–141</sub> | Znt8<sub>186–194</sub> | MAP3865c<sub>262–275</sub> |
|----------|--------|--------------|----------|----------|-----------------|-----------------|-----------------|-----------------|-----------------|
| HT.71    | F      | 60           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.72    | F      | 45           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.73    | F      | 45           | NA       | NA       | +               | +               | +               | –               | +               |
| HT.74    | F      | 61           | +        | +        | –               | –               | –               | –               | –               |
| HT.75    | M      | 58           | +        | NA       | NA              | –               | –               | –               | –               |
| HT.76    | F      | 49           | NA       | NA       | +               | –               | –               | –               | –               |
| HT.77    | F      | 33           | NA       | NA       | +               | +               | +               | –               | –               |
| HT.78    | F      | 47           | –         | +        | +               | +               | +               | +               | +               |
| HT.79    | F      | 53           | NA       | NA       | –               | –               | +               | –               | –               |
| HT.80    | F      | 54           | NA       | NA       | +               | +               | +               | +               | +               |
| HT.81    | F      | 47           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.82    | F      | 41           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.83    | F      | 58           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.84    | F      | 73           | –         | +        | –               | –               | –               | –               | –               |
| HT.85    | F      | 46           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.86    | F      | 66           | +         | –        | –               | –               | –               | –               | –               |
| HT.87    | F      | 39           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.88    | F      | 47           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.89    | F      | 40           | +         | +        | –               | +               | –               | +               | –               |
| HT.90    | F      | 16           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.91    | F      | 63           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.92    | F      | 51           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.93    | F      | 41           | NA       | NA       | +               | +               | +               | +               | –               |
| HT.94    | F      | 40           | +         | –        | –               | –               | –               | –               | –               |
| HT.95    | F      | 53           | –         | –        | –               | –               | –               | –               | –               |
| HT.96    | F      | 59           | NA       | NA       | –               | –               | –               | –               | +               |
| HT.97    | F      | 35           | –         | –        | –               | –               | –               | –               | –               |
| HT.98    | F      | 52           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.99    | F      | 23           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.100   | F      | 43           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.101   | F      | 21           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.102   | F      | 52           | NA       | NA       | –               | –               | –               | –               | –               |
| HT.103   | M      | 12           | +         | +        | +               | +               | +               | +               | +               |
| HT.104   | F      | 63           | NA       | NA       | –               | –               | –               | –               | +               |
| HT.105   | F      | 10           | NA       | NA       | +               | –               | –               | –               | –               |
We decided to investigate the sero-prevalence of anti-MAP/ZnT8 Abs among Sardinian HT patients. To date, this is the first study producing experimental evidence accounting for an association between MAP presence and HT disease.

**Material and Methods**

**Subjects**

The participants enrolled in this case-control study were 107 individuals affected by Hashimoto's thyroiditis (n = 107; 9 male, 98 female; mean age 45.2±14.6 years), and 100 age and sex-matched healthy controls (HCs). HC subjects were blood donors at the University Hospital of Sassari, with no history of autoimmune disease. All the HT subjects enrolled were attending the Endocrinology Unit of the University Hospital of Sassari, Italy and were diagnosed either according to their history of hypothyroidism with positive antithyroid antibodies, or when there was a diffuse lymphocytic infiltration bilaterally on the pathology report. Patient’s details are provided in Table 1. Serum samples were collected from Vacutainer serum tubes.

**Ethical statement**

All participants signed an informed consent to be enrolled in our study. The study protocols were approved by the ethics committee of the University Hospital of Sassari, Italy.

**Peptides**

Peptides MAP3865c125–133 (MIAVALAGL) and MAP3865c133–141 (LAANFVVAL) along with their respective homologous peptides ZnT8178–186 (MIIVSSCAV), ZnT8186–194 (VAANIVLTV) and MAP3865c262–275 (DSARVLRDARAVLS) were synthesized at > 90% purity (LifeTein, South Plainfield, NJ 07080, USA).

**ELISA**

Indirect ELISAs to detect Abs specific for MAP3865c/ZnT8 homologues peptides and anti-MAP3865c262–275 were carried out as described elsewhere [9]. Finest cut-off points were identified by Receiver operating characteristic (ROC) curves analyses, setting the specificity at 93% (i.e., Ab+ HCs ≤ 7% and the corresponding sensitivity was chosen accordingly. Data was normalized to a positive control serum included in all essays run, whose Ab-reactivity was set at 10,000 arbitrary units (AU)/ml.

**Auto-antibodies assays**

Anti-TPO and anti-TG antibodies titers were measured by chemiluminescence methodology in the serum of 53 and 51 subjects respectively, using the Liaison Anti-TPO kit (DiaSorin, Italy) for anti-TPO assay with normal values ranging from 0–10 U/ml and the Liaison Anti-Tg kit (DiaSorin, Italy) for anti-TG assay with normal values ranging from 0–100 units/ml according to the producer’s instructions.

**Statistical analysis**

Statistical analyses were performed by Graphpad Prism 6.0 software.

**Results**

We investigated whether MAP3865c/ZnT8 homologues peptides, which were highly immunogenic in T1D subjects, could be recognized by HT Sardinian patients. Five MAP3865c/ZnT8 peptides, four belonging to the fourth trans-membrane domain [9] and one newly designed C-terminal peptide MAP3865c262–275

---

**Table 1.**

| Identity | Gender | Age at incl. | Anti TPO | Anti TG | MAP3865c125–133 | MAP3865c133–141 | ZnT8178–186 | ZnT8186–194 | MAP3865c262–275 |
|----------|--------|--------------|----------|---------|-----------------|-----------------|--------------|--------------|-----------------|
| HT.106   | F      | 27           | +        | ++      | +               | +               | +            | +            | +               |
| HT.107   | F      | 60           | NA       | NA      | NA              | NA              | NA           | NA           | NA              |

HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*Identity Gender Age at incl. Anti TPO Anti TG MAP3865c125–133 MAP3865c133–141 ZnT8178–186 ZnT8186–194 MAP3865c262–275 HT.106 F 27 + ++ + HT.107 F 60 NA NA 22 22 2

HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.

*HT: positive Hashimoto's Thyroiditis patient, n = 107; mean age 45.2±14.6 years.

Positive if ≥ 100 U/ml.

Positive if ≥ 10 U/ml.
(DSARVL) were examined in 107 HT, and 100 age matched HCs via our previously set up indirect ELISA [9]. The five peptides were highly recognized proving detectable reactivity. Results are summarized in Fig. 1 and Fig. 2.

MAP 3865c125–133 Abs were detected in 26% of HT subjects and in 7% of HCs, this difference was statistically significant (Fisher exact test: $p = 0.0003$; area under ROC curves AUC = 0.72; Fig. 1A).

ZnT8178–186 Ab-reactivity was slightly lower than the one showed by its homologue MAP3865c125–133 when comparing HT with HCs (21% and 6%, respectively; $p = 0.0022$; AUC = 0.72; Fig. 1B).

The homologous MAP3865c133–141 and ZnT8186–194 peptides (Fig. 1C–D) were recognized by 21% and 20% of HT patients, but only in 6% of HCs (AUC 0.74 and 0.73 respectively; $p = 0.0022$ for MAP3865c133–141 and $p = 0.0038$ for ZnT8186–194).

Abs against MAP3865c262–275 were detected in 21% of HT and in 4% of HC subjects, this difference being statistically significant (Fisher exact test: $p = 0.0003$; AUC = 0.74; Fig. 2).

A correlation analysis revealed that there was a high degree of correlation between titers of Abs recognizing MAP3865c and ZnT8 homologous sequences in both HT patients and HCs (Fig. 3). $R^2 = 0.85$ for both MAP3865c125–133 vs ZnT8178–186 and MAP3865c133–141 vs ZnT8186–194 (Fig. 3 A–B). A similar correlation was found for MAP3865c125–133 vs MAP3865c133–141 and ZnT8178–186 ZnT8186–194 (Fig. 3C–D; $R^2 = 0.82$ and 0.74, respectively).

**Discussion**

MAP asymptomatic infection and sero-reactivity are highly prevalent amongst T1D and MS Sardinian subjects. The aforementioned diseases are acknowledged to be among the most prevalent autoimmune disease in Sardinia (fourth and fifth, respectively). Indeed, Sardu et al. reported that HT is the most common autoimmune disease in Sardinia, and that individuals affected by one autoimmune disease are more likely to develop a second autoimmune disorder [16]. All of this pointing out that there might be a common pathogenic mechanism behind these autoimmune diseases. Besides, MAP has been called forth as a potential environmental trigger of HT [4,5]. The link between MAP and HT was postulated after establishing the presence of viable MAP organism in few Italian subjects suffering from HT disease. MAP was detected by reverse transcription-PCR [4,5].

The objective of this study was to verify the robustness of the postulated association investigating whether ZnT8/MAP peptides could be cross-recognized in HT individuals. We asked whether Abs against these epitopes may be at play in HT in Sardinian
subjects. This hypothesis pictures MAP as a new HT environmental trigger, capable of imitating immunogenic components of the thyroid gland, acting mainly through a molecular mimicry mechanism. Interestingly, ZnT8 is expressed in pancreatic β-cells and in the follicle epithelial cells and parafollicular cells lining the thyroid follicle.

Our study shows that Abs against mycobacterial (MAP3865c125–133, MAP3865c133–141, MAP3865c281–287) in conjunction with Abs against human (ZnT8178–186 and ZnT8186–194) epitopes are highly common in HT from Sardinia, but barely detectable in age and sex matched HCs.

Of note, titers against MAP3865c133–141 and MAP3865c125–133 epitopes were very similar to the one displayed by the human homologous peptides (ZnT8186–194, and ZnT8178–186) in HT and healthy subjects, with a percent fraction of Ab+ sera ranging from 20% to 26%.

Indirect ELISAs highlighted a very similar reactivity against MAP3865c/ZnT8 homologues epitopes accounting for an Ab-mediated cross-recognition. Indeed, correlation analyses confirm that Abs recognizing homologous MAP3865c/ZnT8 sequences segregate within the same sera.

Figure 2. Scatter plots representing the IgG antibodies distribution against MAP3865262–275 C-terminal epitope in Hashimoto’s thyroiditis patients compared to healthy controls. Data representation is the same as in Figure 1. doi:10.1371/journal.pone.0097621.g002

Figure 3. Relationship between titers of MAP3865c and ZnT8-reactive Abs recognizing different epitopes. A significant correlation was found between titers of IgG antibodies recognizing MAP3865c125–133 and its homologous ZnT8178–186 epitope (A) and MAP3865c133–141 and its homologous ZnT8186–194 (B). A significant correlation was also observed between MAP3865c125–133 and its consecutive MAP3865c133–141 epitope (C) and ZnT8178–186 and its consecutive ZnT8186–194 (D). doi:10.1371/journal.pone.0097621.g003
The fact that ZnT8 has not been found expressed by medullary thymic epithelial cells [17], may suggest that negative selection of ZnT8-reactive T cells may be ineffective.

Therefore, it will be interesting to investigate the existence of autoreactive effector T-cells capable of recognizing MAP3865c/ZnT8 homologous sequences. To date, our newly designed C-terminal peptide MAP3865c262-275 (DSARVLRDARAVLS) present a 53% amino acid identity with ZnT8 326–340 (DSQYVRREIAKLS) epitope, which was recently reported to be a CD4 (+) T cell target in T1D patients [18]. Noteworthy, this is the first report which significantly associates MAP infection with HT. It is still early to conclude whether this is due to a loss of tolerance toward these epitopes, in fact we here provided only evidence accounting for an association between Abs positivity for ZnT8 and MAP homologue epitopes in Sardinian HT individuals. Further studies are clearly needed to test the hypothesis that MAP may represent an important environmental factor capable of triggering HT. Likewise, genetic polymorphism of the host and other environmental factors need to be explored.

Author Contributions
Conceived and designed the experiments: LAS. Performed the experiments: SM. Analyzed the data: SM DC MP LAS. Contributed reagents/materials/analysis tools: LAS MP. Wrote the paper: SM LAS.

References
1. Ahmed R, Al-Shaikh S, Akhtar M (2012) Hashimoto thyroiditis: a century later. Adv Anat Pathol 19(3):161–6.
2. Burek CL, Talor MV (2009) Environmental triggers and autoimmune thyroiditis. J Autoimmun 33(3–4):183–189.
3. Caturegli P, Kimura H, Rocchi R, Rose NR (2007) Autoimmune thyroid diseases. Curr Opin Rheumatol 19(3):44–48.
4. Sisto M, Cucci L, D’Amore M, Dow TC, Mitolo V, et al. (2010) Proposing a relationship between Mycobacterium avium subspecies paratuberculosis infection and Hashimoto’s thyroiditis. Scand J Infect Dis 42(10):787–90.
5. D’Amore M, Liu S, Sisto M, Cucci L, Dow CT (2010) Molecular identification of Mycobacterium avium subspecies paratuberculosis in an Italian patient with Hashimoto’s thyroiditis and Mollerksen-Rosenthal syndrome. J Med Microbiol 59( Pt 1):137–9.
6. Cosso D, Masala S, Sechi LA (2013) A Sardinian map for multiple sclerosis. Future Microbiol 8(2):223–32.
7. Pozzato N, Capello K, Comin A, Toft N, Nielsen SS, et al. (2011) Prevalence of paratuberculosis infection in dairy cattle in Northern Italy. Prev Vet Med 102(1):83–6.
8. Sechi LA, Scania AM, Molicotti P, Cannas S, Mura M, et al. (2005) Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn’s disease in Sardinia. Am J Gastroenterol 100(7):1529–36.
9. Masala S, Paccagnini D, Cosso D, Brezaz V, Pacifico A, et al. (2011) Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. PLoS One 6(10):e26931.
10. Masala S, Zedda MA, Cosso D, Ripoli C, Palermo M, et al. (2013) Zinc Transporter 8 and MAP3865c Homologous Epitopes are Recognized at T1D Onset in Sardinian Children. PLoS One 8(3):e63371.
11. Masala S, Cosso D, Paccoio A, Molicotti P, Sechi LA (2012) Sardinian Type 1 diabetes patients, Transthyretin and Mycobacterium avium subspecies paratuberculosis infection. Gut Pathog 7:12.
12. Bitti ML, Masala S, Capasso F, Rapini N, Piccinini S, et al. (2012) Mycobacterium avium subsp. paratuberculosis in an Italian cohort of type 1 diabetes pediatric patients. Clin Dev Immunol 785262 doi: 10.1155/2012/785262.
13. Nauer SA, Thanigachalam S, Dow CT, Collina MT (2013) Exploring the role of Mycobacterium avium subspecies paratuberculosis in the pathogenesis of type 1 diabetes mellitus: a pilot study. Gut Pathog 15(4):14.
14. Cosso D, Masala S, Cocco E, Paccagnini D, Frau J, et al. (2012) Are Mycobacterium avium subsp. paratuberculosis and Epstein-Barr virus triggers of multiple sclerosis in Sardinia? Mult Scler 18(11):1181–4.
15. Chimienti F, Devergnas S, Favier A, Seve M (2004) Identification and cloning of a β-cell-specific zinc transporter, ZnT8, localized to insulin secretory granules of the pancreas. Diabetes, 53: 2330–2331.
16. Sardu C, Cocco E, Mereu A, Maes A, Cuccu A, et al. (2012) Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7(5):e32407.
17. Bitti ML, Masala S, Cocco E, Seve M (2004) Identification and cloning of a β-cell-specific zinc transporter, ZnT8, localized to insulin secretory granules of the pancreas. Diabetes, 53: 2330–2331.
18. Sardu C, Cocco E, Mereu A, Maes A, Cuccu A, et al. (2012) Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7(5):e32407.
19. Derbinski J, Gabler J, Brors B, Tierling S, Joumakky S, et al. (2005) Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. http://www.ncbi.nlm.nih.gov/pubmed/?term = Derbinski+J%2C+Gabler+J%2C+Brors+B%2C+Tierling+S%2C+Joumakky S+202(1):33–45.
20. Chiojo D, Focacca E, Nguyen TS, Chauasabel D, Banchereau J, et al. (2013) ZnT8-Specific CD4+ T cells display distinct cytokine expression profiles between type 1 diabetes patients and healthy adults. PLoS One 8(2):e55595.